Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT05635838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.
Study identification
- NCT ID
- NCT05635838
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2022
- Primary completion
- Oct 18, 2023
- Completion
- Mar 13, 2024
- Last update posted
- Oct 31, 2024
2022 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Dermatology Specialists Phoenix | Phoenix | Arizona | 85006 | — |
| First Oc Dermatology | Fountain Valley | California | 92708 | — |
| Skin Care Research, Llc Scr Hollywood | Boca Raton | Florida | 33486 | — |
| Forcare Clinical Research | Tampa | Florida | 33613 | — |
| Marietta Dermatology the Skin Cancer Center Marietta | Marietta | Georgia | 30060-1047 | — |
| Delricht Research | Baton Rouge | Louisiana | 70809 | — |
| Delricht Research | New Orleans | Louisiana | 70115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Revival Research Institute, Llc Troy | Troy | Michigan | 48084 | — |
| Dr Bobby Buka, Md Greenwich Village | New York | New York | 10012-1354 | — |
| Dermatology Associates of Plymouth Meeting | Plymouth Meeting | Pennsylvania | 19462 | — |
| International Clinical Research Tennessee Llc | Murfreesboro | Tennessee | 37130 | — |
| Austin Institute For Clinical Research Aicr Pflugerville | Pflugerville | Texas | 78660 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Dermatology Specialists of Spokane | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05635838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05635838 live on ClinicalTrials.gov.